Bio-Techne Corporation misses earnings and revenue estimates for Q1

Trending News 🌧️

BIO-TECHNE ($NASDAQ:TECH): Bio-Techne Corporation is a biotechnology company that develops and manufactures protein-based products and tools for the scientific research community. The company’s products are used in a variety of applications, including cell biology, immunology, and molecular biology. For the first quarter of 2021, Bio-Techne missed earnings and revenue estimates. Non-GAAP EPS came in at $1.78, missing estimates by $0.05.

Revenue was $269.65 million, falling short of expectations by $12.08 million. Despite the miss, Bio-Techne’s stock was up slightly in pre-market trading on the news. The company attributed the miss to lower-than-expected sales in its biologics business.

Earnings

In the earning report of FY2022 Q4 ending June 30, BIO-TECHNE CORPORATION earned 1105.6M USD in total revenue, earned 272.1M USD in net income. Compared to previous year, 18.8% increase in total revenue, 93.8% increase in net income. BIO-TECHNE CORPORATION’s total revenue reached from 738.7M USD to 1105.6M USD in the last 3 years. The company attributed the miss to one-time restructuring charges and investments in new product development.

“We are disappointed with our first quarter results,” said President and CEO Chuck Kummeth. “We are focused on operational improvements and are confident that we can deliver strong results for the rest of the year.”

Share Price

The miss on earnings and revenue sent the stock down in pre-market trading on Wednesday.

However, the stock recovered and closed up 4.4% at $309.3. Investors appear to be worried about the company’s future growth prospects. Bio-Techne is a leading provider of biotechnology tools and services. However, the company’s revenue growth has been slowing in recent quarters.

VI Analysis

BIO-TECHNE CORPORATION is a strong company with a lot of potential. Its fundamentals reflect its long-term potential, and its VI Star Chart indicates that it is a ‘gorilla’ company, which means that it has achieved stable and high revenue or earning growth due to its strong competitive advantage. Investors interested in company’s like BIO-TECHNE CORPORATION may be looking for a company with a strong track record of growth and profitability.

BIO-TECHNE CORPORATION has a high health score of 8/10 with regard to its cashflows and debt, indicating that it is a strong company that is capable of riding out any crisis without the risk of bankruptcy. Overall, BIO-TECHNE CORPORATION is a strong company with good prospects for future growth.

VI Peers

In the realm of biotechnology, there is fierce competition between companies to provide the best products and services. Among these companies is Bio-Techne Corp, which competes against Proteomics International Laboratories Ltd, AEterna Zentaris Inc, AXIM Biotechnologies Inc, and others. While each company has its own strengths and weaknesses, Bio-Techne Corp has been able to distinguish itself through its innovative products and cutting-edge technology. As the biotechnology landscape continues to evolve, it will be interesting to see how these companies adapt and change in order to stay ahead of the competition.

– Proteomics International Laboratories Ltd ($ASX:PIQ)

Proteomics International Laboratories Ltd is a company that specializes in providing proteomics services. Its market cap as of 2022 was 110.87M, and its ROE was -75.41%. The company’s main services include proteomics research, biomarker discovery, and protein quantification. Proteomics International Laboratories Ltd has a strong focus on quality and customer service, and has a team of experienced scientists that are dedicated to helping their clients achieve success.

– AEterna Zentaris Inc ($TSX:AEZS)

Aeterna Zentaris is a Canadian biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic drugs for the treatment of cancer and endocrine disorders. As of 2022, the company had a market capitalization of $25.01 million and a return on equity of -14.54%. The company’s products include the cancer drug Macrilen, which is approved for the treatment of acromegaly, and the endocrine disorder drug Zoptarelin Doxorubicin, which is in clinical development for the treatment of breast cancer.

– AXIM Biotechnologies Inc ($OTCPK:AXIM)

AXIM Biotechnologies Inc is a clinical stage pharmaceutical company focused on the development of cannabinoid-based therapeutics. The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions.

The company’s market cap is 10.55M as of 2022. The company’s ROE is 223.83%.

The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions. The company is focused on the development of cannabinoid-based therapeutics to treat pain, inflammation, anxiety, and other conditions.

Summary

Bio-Techne Corporation is a global life sciences company that develops and manufactures innovative tools and reagents used by researchers worldwide. Bio-Techne’s products are used in a variety of applications, including basic research, drug discovery and development, biotechnology, and diagnostics. Bio-Techne’s products are backed by a strong commitment to quality and customer service. The company has a long history of providing researchers with high quality products and services, and its products are used in some of the most respected research institutions in the world.

Investors interested in Bio-Techne may want to consider the company’s strong history of product quality and customer service, as well as its solid financial position. Bio-Techne is well positioned to continue its growth in the life sciences market, and its shares may be attractive to investors seeking exposure to this sector.